Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
3/A - YD Bio Ltd (0002011674) (Issuer)
Taipei, Taiwan, March 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company and EG BioMed Co., Ltd., a Taiwan registered company ("EG BioMed"), officially launched the EG Telehealth Platform, https://mdi.eg-bio.com, which marks a significant milestone in the Company's commercialization of early cancer detection and decentralized clinical service delivery across the United States. The platform is now live and enables access across 44 U.S. states, plus Washington, D.C. and Guam, supported by a nationwide network
Taipei, Taiwan, March 17, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio Ltd" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today highlighted the strategic roadmap shared by CEO Dr. Ethan Shen in a recent interview with PharmaBoardroom, a UK-based platform providing insights to the global healthcare and life sciences community. Moving beyond the traditional single-asset biotech model, YD Bio Ltd is building a comprehensive ecosystem that synchronizes diagnostic intelligence with advanced therapeutic execution. In the interview, Dr. Shen addressed the Company's approach to the biotech
Taipei, Taiwan, Feb. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio Ltd" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its subsidiary YD Bio USA, Inc. ("YD Bio USA") entered into a Master Strategic Alliance Agreement (the "Agreement") with YC Biotech Co., Ltd. ("YC Biotech") on February 24, 2026. This partnership represents a pivotal advancement in the Company's mission, establishing YD Bio USA as the official strategic hub and exclusive U.S. Agent for regulatory applications to the U.S. Food and Drug Administration (the "FDA") for YC Biotech's Contract Research
424B3 - YD Bio Ltd (0002011674) (Filer)
6-K - YD Bio Ltd (0002011674) (Filer)
424B3 - YD Bio Ltd (0002011674) (Filer)